Enzymes then modify or conjugate these compounds so they can be transported out of the liver
Between the 2000s and 2010s, as gemcitabine showed good antitumor activity and tolerability, it began to be extended to other solid tumors: In 2002, the FDA approved the combination of gemcitabine and cisplatin for non-small cell lung cancer (NSCLC), and compared with cisplatin alone, the OS was significantly prolonged, becoming one of the first-line standard regimens for NSCLC (Gou et al., 2024)
The FDA regulates medical devices and treatments to ensure patient safety standards are maintained
Cagrilintide dosage with tirzepatide explained: how each compound is titrated, appetite effects, mechanism, and why no combination is approved
Helps to detox the liver and protect its sulfur-rich antioxidant pathways